1,803
Views
21
CrossRef citations to date
0
Altmetric
Original Research

The multidrug-resistance transporter Abcc3 protects NK cells from chemotherapy in a murine model of malignant glioma

, , , , , & show all
Article: e1108513 | Received 26 Jun 2015, Accepted 10 Oct 2015, Published online: 19 Apr 2016

References

  • Stupp R, Mason W, van den Bent MJ, Weller M, Fisher BM, Taphoorn MJB, Belanger K, Brandes AA, Marosi C, Bogdahn U et al. Radiotherapy plus Concomitant\nand Adjuvant Temozolomide for Glioblastoma. N Engl J Med 2005; 352:987-96; PMID:15758009; http://dx.doi.org/10.1056/NEJMoa043330
  • Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJB, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009; 10:459-66; PMID:19269895; http://dx.doi.org/10.1016/S1470-2045(09)70025-7
  • Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G. Immunological aspects of cancer chemotherapy. Nat Rev Immunol 2008; 8:59-73; PMID:18097448; http://dx.doi.org/10.1038/nri2216
  • Galluzzi L, Senovilla L, Zitvogel L, Kroemer G. The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov [Internet] 2012 [cited 2012 Oct 31]; 11:215-33. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22301798; PMID:22301798; http://dx.doi.org/10.1038/nrd3626
  • Emens LA, Jaffee EM. Leveraging the activity of tumor vaccines with cytotoxic chemotherapy. Cancer Res 2005; 65:8059-64; PMID:16166275; http://dx.doi.org/10.1158/0008-5472.CAN-05-1797
  • Sampson JH, Aldape KD, Archer GE, Coan A, Desjardins A, Friedman AH, Friedman HS, Gilbert MR, Herndon JE, McLendon RE et al. Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. Neuro Oncol 2011; 13:324-33; PMID:21149254; http://dx.doi.org/10.1093/neuonc/noq157
  • Jordan JT, Sun W, Hussain SF, DeAngulo G, Prabhu SS, Heimberger AB. Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy. Cancer Immunol Immunother [Internet] 2008 [cited 2012 Dec 11]; 57:123-31. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17522861; PMID:17522861; http://dx.doi.org/10.1007/s00262-007-0336-x
  • Kim T-G, Kim CKC-H, Park J-S, Park S-D, Kim CKC-H, Chung D-S, Hong Y-K. Immunological factors relating to the antitumor effect of temozolomide chemoimmunotherapy in a murine glioma model. Clin Vaccine Immunol [Internet] 2010 [cited 2014 Jan 9]; 17:143-53. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2812079&tool=pmcentrez&rendertype=abstract; PMID:19889936; http://dx.doi.org/10.1128/CVI.00292-09
  • Alizadeh D, Zhang L, Brown CE, Farrukh O, Jensen MC, Badie B. Induction of anti-glioma natural killer cell response following multiple low-dose intracerebral CpG therapy. Clin Cancer Res 2010; 16:3399-408; PMID:20570924; http://dx.doi.org/10.1158/1078-0432.CCR-09-3087
  • Cantini G, Pisati F, Pessina S, Finocchiaro G, Pellegatta S. Immunotherapy against the radial glia marker GLAST effectively triggers specific antitumor effectors without autoimmunity. Oncoimmunology [Internet] 2012; 1:884-93. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3489744&tool=pmcentrez&rendertype=abstract; PMID:23162756; http://dx.doi.org/10.4161/onci.20637
  • Pellegatta S, Eoli M, Frigerio S, Antozzi C, Bruzzone MG, Cantini G, Nava S, Anghileri E, Cuppini L, Cuccarini V et al. The natural killer cell response and tumor debulking are associated with prolonged survival in recurrent glioblastoma patients receiving dendritic cells loaded with autologous tumor lysates. Oncoimmunology [Internet] 2013; 2:e23401. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3661164&tool=pmcentrez&rendertype=abstract; PMID:23802079; http://dx.doi.org/10.4161/onci.23401
  • Banissi C, Ghiringhelli F, Chen L, Carpentier AF. Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model. Cancer Immunol Immunother 2009; 58:1627-34; PMID:19221744; http://dx.doi.org/10.1007/s00262-009-0671-1
  • Oselin K, Mrozikiewicz PM, Pähkla R, Roots I. Quantitative determination of the human MRP1 and MRP2 mRNA expression in FACS-sorted peripheral blood CD4+, CD8+, CD19+, and CD56+ cells. Eur J Haematol 2003; 71:119-23; PMID:12890151; http://dx.doi.org/10.1034/j.1600-0609.2003.00100.x
  • Donnenberg VS, Burckart GJ, Zeevi A, Griffith BP, Iacono A, McCurry KR, Wilson JW, Donnenberg AD. P-glycoprotein activity is decreased in CD4+ but not CD8+ lung allograft-infiltrating T cells during acute cellular rejection. Transplantation 2004; 77:1699-706; PMID:15201669; http://dx.doi.org/10.1097/01.TP.0000131163.43015.85
  • Van de Ven R, Oerlemans R, van der Heijden JW, Scheffer GL, de Gruijl TD, Jansen G, Scheper RJ. ABC drug transporters and immunity: novel therapeutic targets in autoimmunity and cancer. J Leukoc Biol 2009; 86:1075-87; PMID:19745159; http://dx.doi.org/10.1189/jlb.0309147
  • Glavinas H, Krajcsi P, Cserepes J, Sarkadi B. The role of ABC transporters in drug resistance, metabolism and toxicity. Curr Drug Deliv [Internet] 2004 [cited 2015 Feb 9]; 1:27-42. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16305368; PMID:16305368; http://dx.doi.org/10.2174/1567201043480036
  • Liston P, Fong WG, Korneluk RG. The inhibitors of apoptosis: there is more to life than Bcl2. Oncogene [Internet] 2003 [cited 2015 Jan 13]; 22:8568-80. Available from: http://www.ncbi.nlm.nih.gov/pubmed/14634619; PMID:14634619; http://dx.doi.org/10.1038/sj.onc.1207101
  • Kuwata K, Watanabe H, Jiang S-Y, Yamamoto T, Tomiyama-Miyaji C, Abo T, Miyazaki T, Naito M. AIM inhibits apoptosis of T cells and NKT cells in Corynebacterium-induced granuloma formation in mice. Am J Pathol [Internet] 2003 [cited 2015 Feb 9]; 162:837-47. Available from:http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1868086&tool=pmcentrez&rendertype=abstract; PMID:12598318; http://dx.doi.org/10.1016/S0002-9440(10)63880-1
  • Cai W, Shen F, Li J, Feng Z, Wang Y, Xiao H, Xu B. Activated protease receptor-2 induces GATA6 expression to promote survival in irradiated colon cancer cells. Arch Biochem Biophys [Internet] 2014 [cited 2015 Feb 9]; 555-556:28-32. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24887481; PMID:24887481; http://dx.doi.org/10.1016/j.abb.2014.05.021
  • Wan X, Zhang L, Jiang B. Role of endothelin B receptor in oligodendroglioma proliferation and survival: In vitro and in vivo evidence. Mol Med Rep [Internet] 2014 [cited 2015 Feb 9]; 9:229-34. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24145738; PMID:24145738; http://dx.doi.org/10.3892/mmr.2013.1746
  • Zamora DO, Babra B, Pan Y, Planck SR, Rosenbaum JT. Human leukocytes express ephrinB2 which activates microvascular endothelial cells. Cell Immunol [Internet] 2006 [cited 2015 Feb 9]; 242:99-109. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17123494; PMID:17123494; http://dx.doi.org/10.1016/j.cellimm.2006.10.001
  • Bergström S-E, Bergdahl E, Sundqvist K-G. A cytokine-controlled mechanism for integrated regulation of T-lymphocyte motility, adhesion and activation. Immunology [Internet] 2013 [cited 2015 Feb 9]; 140:441-55. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3839648&tool=pmcentrez&rendertype=abstract; PMID:23866045; http://dx.doi.org/10.1111/imm.12154
  • Ewen CL, Kane KP, Bleackley RC. A quarter century of granzymes. Cell Death Differ [Internet] 2012 [cited 2015 Feb 9]; 19:28-35. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3252830&tool=pmcentrez&rendertype=abstract; PMID:22052191; http://dx.doi.org/10.1038/cdd.2011.153
  • Ostermann S, Csajka C, Buclin T, Leyvraz S, Lejeune F, Decosterd LA, Stupp R. Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients. Clin Cancer Res 2004; 10:3728-36; PMID:15173079; http://dx.doi.org/10.1158/1078-0432.CCR-03-0807
  • Bommhardt U, Chang KC, Swanson PE, Wagner TH, Tinsley KW, Karl IE, Hotchkiss RS. Akt Decreases Lymphocyte Apoptosis and Improves Survival in Sepsis. J Immunol [Internet] 2004; 172:7583-91. Available from: http://www.jimmunol.org/cgi/doi/10.4049/jimmunol.172.12.7583; PMID:15187138; http://dx.doi.org/10.4049/jimmunol.172.12.7583
  • Plas DR, Rathmell JC, Thompson CB. Homeostatic control of lymphocyte survival: potential origins and implications. Nat Immunol 2002; 3:515-21; PMID:12032565; http://dx.doi.org/10.1038/ni0602-515
  • Gan Y, Liu R, Wu W, Bomprezzi R, Shi FD. Antibody to α4 integrin suppresses natural killer cells infiltration in central nervous system in experimental autoimmune encephalomyelitis. J Neuroimmunol 2012; 247:9-15; PMID:22503411; http://dx.doi.org/10.1016/j.jneuroim.2012.03.011
  • Chiossone L, Chaix J, Fuseri N, Roth C, Vivier E, Walzer T. Maturation of mouse NK cells is a 4-stage developmental program. Blood [Internet] 2009 [cited 2013 Apr 4]; 113:5488-96. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19234143; PMID:19234143; http://dx.doi.org/10.1182/blood-2008-10-187179
  • Fu B, Wang F, Sun R, Ling B, Tian Z, Wei H. CD11b and CD27 reflect distinct population and functional specialization in human natural killer cells. Immunology [Internet] 2011 [cited 2013 Dec 7]; 133:350-9. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3112344&tool=pmcentrez&rendertype=abstract; PMID:21506999; http://dx.doi.org/10.1111/j.1365-2567.2011.03446.x
  • Baker GJ, Chockley P, Yadav VN, Doherty R, Ritt M, Sivaramakrishnan S, Castro MG, Lowenstein PR. Natural killer cells eradicate galectin-1-deficient glioma in the absence of adaptive immunity. Cancer Res [Internet] 2014 [cited 2014 Oct 21]; 74:5079-90. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25038230; PMID:25038230; http://dx.doi.org/10.1158/0008-5472.CAN-14-1203
  • Wang W, Guo H, Geng J, Zheng X, Wei H, Sun R, Tian Z. Tumor-released Galectin-3, a soluble inhibitory ligand of human NKp30, plays an important role in tumor escape from NK cell attack. J Biol Chem 2014; 289:33311-9; PMID:25315772; http://dx.doi.org/10.1074/jbc.M114.603464
  • Golden-Mason L, McMahan RH, Strong M, Reisdorph R, Mahaffey S, Palmer BE, Cheng L, Kulesza C, Hirashima M, Niki T et al. Galectin-9 functionally impairs natural killer cells in humans and mice. J Virol [Internet] 2013; 87:4835-45. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3624298&tool=pmcentrez&rendertype=abstract; PMID:23408620; http://dx.doi.org/10.1128/JVI.01085-12
  • Pellegatta S, Poliani PL, Stucchi E, Corno D, Colombo CA, Orzan F, Ravanini M, Finocchiaro G. Intra-tumoral dendritic cells increase efficacy of peripheral vaccination by modulation of glioma microenvironment. Neuro Oncol 2010; 12:377-88; PMID:20308315; http://dx.doi.org/10.1093/neuonc/nop024
  • Michaud A, Dardari R, Charrier E, Cordeiro P, Herblot S, Duval M. IL-7 enhances survival of human CD56bright NK cells. J Immunother 2010; 33:382-90; PMID:20386468; http://dx.doi.org/10.1097/CJI.0b013e3181cd872d
  • Ziblat A, Domaica CI, Spallanzani RG, Iraolagoitia XLR, Rossi LE, Avila DE, Torres NI, Fuertes MB, Zwirner NW. IL-27 stimulates human NK-cell effector functions and primes NK cells for IL-18 responsiveness. Eur J Immunol 2015; 45:192-202; PMID:25308526; http://dx.doi.org/10.1002/eji.201444699
  • Cai J, Zhang W, Yang P, Wang Y, Li M, Zhang C, Wang Z, Hu H, Liu Y, Li Q et al. Identification of a 6-cytokine prognostic signature in patients with primary glioblastoma harboring M2 microglia/macrophage phenotype relevance. PLoS One 2015; 10:e0126022; PMID:25978454; http://dx.doi.org/10.1371/journal.pone.0126022
  • Huang B, Lei Z, Zhao J, Gong W, Liu J, Chen Z, Liu Y, Li D, Yuan Y, Zhang GM et al. CCL2/CCR2 pathway mediates recruitment of myeloid suppressor cells to cancers. Cancer Lett 2007; 252:86-92; PMID:17257744; http://dx.doi.org/10.1016/j.canlet.2006.12.012
  • Maru S V, Holloway KA, Flynn G, Lancashire CL, Loughlin AJ, Male DK, Romero IA. Chemokine production and chemokine receptor expression by human glioma cells: role of CXCL10 in tumour cell proliferation. J Neuroimmunol [Internet] 2008 [cited 2015 Aug 28]; 199:35-45. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18538864; PMID:18538864; http://dx.doi.org/10.1016/j.jneuroim.2008.04.029
  • Triozzi PL, Schoenfield L, Plesec T, Saunthararajah Y, Tubbs RR, Singh AD. Molecular profiling of primary uveal melanomas with tumor-infiltrating lymphocytes. OncoImmunology 2014; 1-8; http://dx.doi.org/10.4161/21624011.2014.947169
  • Conforti R, Ma Y, Morel Y, Paturel C, Terme M, Viaud S, Ryffel B, Ferrantini M, Uppaluri R, Schreiber R et al. Opposing effects of toll-like receptor (TLR3) signaling in tumors can be therapeutically uncoupled to optimize the anticancer efficacy of TLR3 ligands. Cancer Res 2010; 70:490-500; PMID:20068181; http://dx.doi.org/10.1158/0008-5472.CAN-09-1890
  • Peaston AE, Gardaneh M, Franco A V, Hocker JE, Murphy KM, Farnsworth ML, Catchpoole DR, Haber M, Norris MD, Lock RB et al. MRP1 gene expression level regulates the death and differentiation response of neuroblastoma cells. Br J Cancer 2001; 85:1564-71; PMID:11720446; http://dx.doi.org/10.1054/bjoc.2001.2144
  • Caporali S, Levati L, Graziani G, Muzi A, Atzori MG, Bonmassar E, Palmieri G, Ascierto PA, D’Atri S. NF-κB is activated in response to temozolomide in an AKT-dependent manner and confers protection against the growth suppressive effect of the drug. J Transl Med [Internet] 2012; 10:252. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3551789&tool=pmcentrez&rendertype=abstract; PMID:23259744; http://dx.doi.org/10.1186/1479-5876-10-252
  • Bellacosa A, Kumar CC, Cristofano A Di, Testa JR. Activation of AKT kinases in cancer: Implications for therapeutic targeting. Adv. Cancer Res.2005; 94:29-86; PMID:16095999; http://dx.doi.org/10.1016/S0065-230X(05)94002-5
  • Chiarini F, Del Sole M, Mongiorgi S, Gaboardi GC, Cappellini A, Mantovani I, Follo MY, McCubrey JA, Martelli AM. The novel Akt inhibitor, perifosine, induces caspase-dependent apoptosis and downregulates P-glycoprotein expression in multidrug-resistant human T-acute leukemia cells by a JNK-dependent mechanism. Leukemia 2008; 22:1106-16; PMID:18385752; http://dx.doi.org/10.1038/leu.2008.79
  • Tazzari PL, Cappellini A, Ricci F, Evangelisti C, Papa V, Grafone T, Martinelli G, Conte R, Cocco L, McCubrey JA et al. Multidrug resistance-associated protein 1 expression is under the control of the phosphoinositide 3 kinase/Akt signal transduction network in human acute myelogenous leukemia blasts. Leukemia 2007; 21:427-38; PMID:17215852; http://dx.doi.org/10.1038/sj.leu.2404523
  • Bleau AM, Hambardzumyan D, Ozawa T, Fomchenko EI, Huse JT, Brennan CW, Holland EC. PTEN/PI3K/Akt Pathway Regulates the Side Population Phenotype and ABCG2 Activity in Glioma Tumor Stem-like Cells. Cell Stem Cell 2009; 4:226-35; PMID:19265662; http://dx.doi.org/10.1016/j.stem.2009.01.007
  • Su YC, Li SC, Hsu CK, Yu CC, Lin TJ, Lee CY, Liao HF. G-CSF downregulates natural killer cell-mediated cytotoxicity in donors for hematopoietic SCT. Bone Marrow Transplant 2012; 47:73-81; PMID:21358682; http://dx.doi.org/10.1038/bmt.2011.22
  • Segovis CM, Schoon RA, Dick CJ, Nacusi LP, Leibson PJ, Billadeau DD. PI3K links NKG2D signaling to a CrkL pathway involved in natural killer cell adhesion, polarity, and granule secretion. J Immunol 2009; 182:6933-42; PMID:19454690; http://dx.doi.org/10.4049/jimmunol.0803840
  • Kim N, Saudemont A, Webb L, Camps M, Ruckle T, Hirsch E, Turner M, Colucci F. The p110delta catalytic isoform of PI3K is a key player in NK-cell development and cytokine secretion. Blood 2007; 110:3202-8; PMID:17644738; http://dx.doi.org/10.1182/blood-2007-02-075366
  • Wai L-E, Fujiki M, Takeda S, Martinez OM, Krams SM. Rapamycin, But Not Cyclosporine or FK506, Alters Natural Killer Cell Function. Transplantation 2008; 85:145-9; PMID:18192925; http://dx.doi.org/10.1097/01.tp.0000296817.28053.7b
  • Miletti-González KE, Chen S, Muthukumaran N, Saglimbeni GN, Wu X, Yang J, Apolito K, Shih WJ, Hait WN, Rodriguez-Rodriguez L. The CD44 receptor interacts with P-glycoprotein to promote cell migration and invasion in cancer. Cancer Res 2005; 65:6660-7; PMID:16061646; http://dx.doi.org/10.1158/0008-5472.CAN-04-3478
  • Honig SM, Fu S, Mao X, Yopp A, Gunn MD, Randolph GJ, Bromberg JS. FTY720 stimulates multidrug transporter- and cysteinyl leukotriene-dependent T cell chemotaxis to lymph nodes. J Clin Invest 2003; 111:627-37; PMID:12618517; http://dx.doi.org/10.1172/JCI200316200
  • Robertson MJ. Role of chemokines in the biology of natural killer cells. J Leukoc Biol [Internet] 2002; 71:173-83. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11818437; PMID:11818437
  • Franciszkiewicz K, Boissonnas A, Boutet M, Combadière C, Mami-Chouaib F. Role of chemokines and chemokine receptors in shaping the effector phase of the antitumor immune response. Cancer Res 2012; 72:6325-32; PMID:23222302; http://dx.doi.org/10.1158/0008-5472.CAN-12-2027
  • Alvino E, Pepponi R, Pagani E, Lacal PM, Nunziata C, Bonmassar E, D’Atri S. O(6)-benzylguanine enhances the in vitro immunotoxic activity of temozolomide on natural or antigen-dependent immunity. J Pharmacol Exp Ther 1999; 291:1292-300; PMID:10565854
  • Ellsworth S, Balmanoukian A, Kos F, Nirschl CJ, Nirschl TR, Grossman S A, Luznik L, Drake CG. Sustained CD4(+) T cell-driven lymphopenia without a compensatory IL-7/IL-15 response among high-grade glioma patients treated with radiation and temozolomide. Oncoimmunology [Internet] 2014; 3:e27357. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24790790; PMID:24790790; http://dx.doi.org/10.4161/onci.27357
  • Fernandez NC, Lozier A, Flament C, Ricciardi-Castagnoli P, Bellet D, Suter M, Perricaudet M, Tursz T, Maraskovsky E, Zitvogel L. Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo. Nat Med [Internet] 1999; 5:405-11. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10202929; PMID:10202929; http://dx.doi.org/10.1038/7403
  • Moretta A. Natural killer cells and dendritic cells: rendezvous in abused tissues. Nat Rev Immunol [Internet] 2002 [cited 2013 Jun 7]; 2:957-64. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12461568; PMID:12461568; http://dx.doi.org/10.1038/nri956
  • Van Elssen CHMJ, Oth T, Germeraad WT V, Bos GMJ, Vanderlocht J. Natural killer cells: the secret weapon in dendritic cell vaccination strategies. Clin Cancer Res [Internet] 2014 [cited 2014 Mar 29]; 20:1095-103. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24590885; PMID:24590885; http://dx.doi.org/10.1158/1078-0432.CCR-13-2302
  • Lowdell MW. Natural killer cells in haematopoietic stem cell transplantation. Transfus Med [Internet] 2003; 13:399-404. Available from: http://www.ncbi.nlm.nih.gov/pubmed/14651745; PMID:14651745; http://dx.doi.org/10.1111/j.1365-3148.2003.00467.x
  • Köck K, Grube M, Jedlitschky G, Oevermann L, Siegmund W, Ritter CA, Kroemer HK. Expression of adenosine triphosphate-binding cassette (ABC) drug transporters in peripheral blood cells: relevance for physiology and pharmacotherapy. Clin Pharmacokinet [Internet] 2007; 46:449-70. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17518506; PMID:17518506; http://dx.doi.org/10.2165/00003088-200746060-00001
  • Sengupta S, Marrinan J, Frishman C, Sampath P. Impact of temozolomide on immune response during malignant glioma chemotherapy. Clin Dev Immunol 2012; 2012:831090; PMID:23133490; http://dx.doi.org/10.1155/2012/831090
  • Litterman AJ, Zellmer DM, Grinnen KL, Hunt M A, Dudek AZ, Salazar AM, Ohlfest JR. Profound Impairment of Adaptive Immune Responses by Alkylating Chemotherapy. J Immunol [Internet] 2013 [cited 2013 May 28]; PMID:23686484; http://dx.doi.org/10.4049/jimmunol.1203539.
  • Roos W, Baumgartner M, Kaina B. Apoptosis triggered by DNA damage O6-methylguanine in human lymphocytes requires DNA replication and is mediated by p53 and Fas/CD95/Apo-1. Oncogene 2004; 23:359-67; PMID:14724564; http://dx.doi.org/10.1038/sj.onc.1207080
  • Asavaroengchai W, Kotera Y, Mulé JJ. Tumor lysate-pulsed dendritic cells can elicit an effective antitumor immune response during early lymphoid recovery. Proc Natl Acad Sci U S A 2002; 99:931-6; PMID:11792864; http://dx.doi.org/10.1073/pnas.022634999
  • Sanchez-Perez LA, Choi BD, Archer GE, Cui X, Flores C, Johnson LA, Schmittling RJ, Snyder D, Herndon JE, Bigner DD et al. Myeloablative temozolomide enhances CD8+ T-cell responses to vaccine and is required for efficacy against brain tumors in mice. PLoS One [Internet] 2013 [cited 2014 Mar 16]; 8:e59082. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3601076&tool=pmcentrez&rendertype=abstract; PMID:23527092; http://dx.doi.org/10.1371/journal.pone.0059082
  • Iversen TZ, Brimnes MK, Nikolajsen K, Andersen RS, Hadrup SR, Andersen MH, Bastholt L, Svane IM. Depletion of T lymphocytes is correlated with response to temozolomide in melanoma patients. Oncoimmunology [Internet] 2013; 2:e23288. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3601183&tool=pmcentrez&rendertype=abstract; PMID:23525955; http://dx.doi.org/10.4161/onci.23288
  • Fadul CE, Fisher JL, Gui J, Hampton TH, Côté AL, Ernstoff MS. Immune modulation effects of concomitant temozolomide and radiation therapy on peripheral blood mononuclear cells in patients with glioblastoma multiforme. Neuro Oncol 2011; 13:393-400; PMID:21339188; http://dx.doi.org/10.1093/neuonc/noq204
  • Lee KM, Bhawan S, Majima T, Wei H, Nishimura MI, Yagita H, Kumar V. Cutting edge: the NK cell receptor 2B4 augments antigen-specific T cell cytotoxicity through CD48 ligation on neighboring T cells. J Immunol 2003; 170:4881-5; PMID:12734329; http://dx.doi.org/10.4049/jimmunol.170.10.4881
  • Assarsson E, Kambayashi T, Schatzle JD, Cramer SO, von Bonin A, Jensen PE, Ljunggren HG, Chambers BJ. NK Cells Stimulate Proliferation of T and NK Cells through 2B4/CD48 Interactions. J Immunol 2004; 173:174-80; PMID:15210772; http://dx.doi.org/10.4049/jimmunol.173.1.174